NCT06177431View on ClinicalTrials.gov

An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 13, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Motor Neuron Disease
Interventions
DRUG

Monepantel

Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals

Trial Locations (2)

2109

Macquarie University, Sydney

3195

Calvary Health Care Bethlehem, Melbourne

Sponsors
All Listed Sponsors
collaborator

Calvary Health Care Bethlehem

UNKNOWN

collaborator

Macquarie University, Australia

OTHER

lead

Neurizon Therapeutics Limited

INDUSTRY

NCT06177431 - An Open Label Extension Study of Monepantel in Individuals With Motor Neurone Disease | Biotech Hunter | Biotech Hunter